| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02950168 | Atrial Fibrillation|Venous Thromboembolism | Procedure: Edoxaban | Daiichi Sankyo Inc.|SSS International Clinical Research GmBH|Hippocrates Research|IMS Health|ITEC Services | | 2016-11-01 | 2016-10-28 |
| NCT02943993 | Venous Thromboembolism | Drug: Edoxaban | Daiichi Sankyo Inc.|Quintiles, Inc.|SSS International Medical Research GmbH|Hippocrates Research|IMS Health|ITEC Services | | 2015-08-01 | 2016-10-26 |
| NCT02964949 | Atrial Fibrillation | Drug: Edoxaban | Daiichi Sankyo Inc.|Quintiles, Inc. | | 2017-01-24 | 2017-02-28 |
| NCT02952599 | Venous Thromboembolism | Drug: Edoxaban | Daiichi Sankyo Inc.|Quintiles, Inc.|A+ Inc. | | 2017-03-01 | 2016-11-01 |
| NCT03088072 | Non-Valvular Atrial Fibrillation|Left Atrial Appendage Closure | Drug: Edoxaban|Device: WATCHMAN LAA Closure|Drug: Aspirin and Clopidogrel|Drug: Aspirin and Warfarin | Scripps Health|Daiichi Sankyo Inc. | Phase 4 | 2017-03-29 | 2017-03-17 |
| NCT02944019 | Atrial Fibrillation | Drug: Edoxaban | Daiichi Sankyo Inc.|Quintiles, Inc.|SSS International Clinical Research GmBH|Hippocrates Research|IMS Health|ITEC Services | | 2015-08-01 | 2016-10-26 |
| NCT02951039 | Atrial Fibrillation | Drug: Edoxaban | Daiichi Sankyo Inc.|Quintiles, Inc.|A+ Inc. | | 2017-03-01 | 2016-10-28 |
| NCT02567461 | Coronary Artery Disease | Drug: Edoxaban 60 mg|Drug: Edoxaban 30 mg|Drug: Clopidogrel 75 mg|Drug: Aspirin 81 mg | University of Florida|Daiichi Sankyo Inc. | Phase 4 | 2016-03-01 | 2017-03-15 |
| NCT02448901 | Heart Failure | Drug: Edoxaban | LifeBridge Health|Daiichi Sankyo Inc. | | 2015-04-01 | 2015-05-15 |
| NCT02561897 | Atrial Fibrillation | Drug: Edoxaban|Drug: Warfarin | Electrophysiology Research Foundation|Axio Research Corporation | Phase 4 | 2015-12-01 | 2017-03-08 |
| NCT02221102 | Ischemia|Stroke|Cerebral Infarction | Drug: Aspirin|Drug: edoxaban|Drug: placebo | Xijing Hospital | Phase 2|Phase 3 | 2013-12-01 | 2014-08-18 |
| NCT00781391 | Stroke|Atrial Fibrillation|Embolism | Drug: warfarin tablets|Drug: Edoxaban tablets (high dose regimen-60mg)|Drug: Edoxaban tablets (low dose regimen-30mg)|Drug: placebo warfarin|Drug: placebo edoxaban | Daiichi Sankyo Inc.|The TIMI Study Group | Phase 3 | 2008-11-01 | 2015-03-12 |
| NCT02072434 | Atrial Fibrillation | Drug: edoxaban|Drug: Enoxaparin|Drug: Warfarin | Daiichi Sankyo Inc.|Covance|Quintiles, Inc. | Phase 3 | 2014-03-01 | 2017-01-03 |
| NCT02866175 | Atrial Fibrillation | Drug: Edoxaban|Drug: Clopidogrel|Drug: Prasugrel|Drug: ticagrelor | Daiichi Sankyo Inc.|European Cardiovascular Research Institute|Kompetenznetz Vorhofflimmern e.V.|Chiltern International Inc. | Phase 3 | 2017-02-01 | 2016-08-10 |
| NCT02207257 | Anticoagulation Reversal | Drug: PER977|Drug: Placebo | Perosphere, Inc.|Quintiles, Inc. | Phase 2 | 2014-03-01 | 2016-09-26 |
| NCT00986154 | Venous Thromboembolism|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Thromboembolism|Venous Thrombosis | Drug: edoxaban tosylate(DU-176b)|Drug: low molecular weight heparin/unfractionated heparin|Drug: warfarin | Daiichi Sankyo Inc. | Phase 3 | 2009-10-01 | 2015-03-13 |
| NCT01802775 | Peripheral Arterial Disease | Drug: edoxaban|Drug: Clopidogrel|Drug: Aspirin | Daiichi Sankyo Inc.|UMC Utrecht | Phase 2 | 2013-01-01 | 2015-11-18 |
| NCT02942576 | Atrial Fibrillation | Drug: Edoxaban|Drug: VKA-Based Regimen|Drug: VKA-Based Regimen|Drug: VKA-Based Regimen|Drug: VKA-Based Regimen | Daiichi Sankyo Europe, GmbH|Daiichi Sankyo Inc. | Phase 3 | 2017-03-01 | 2016-10-21 |
| NCT01662908 | Deep Vein Thrombosis|Venous Thrombosis | Drug: edoxaban tosylate|Drug: enoxaparin/unfractionated heparin|Drug: warfarin | Daiichi Sankyo Inc. | Phase 2 | 2012-08-01 | 2015-03-26 |
| NCT02303431 | Deep Vein Thrombosis|Venous Thromboembolism | Drug: Edoxaban low dose|Drug: Edoxaban high dose | Daiichi Sankyo Inc.|Medpace, Inc. | Phase 1 | 2014-08-01 | 2017-03-22 |
| NCT02798471 | Venous Thromboembolism (VTE)|Pulmonary Embolism|Deep Vein Thrombosis (DVT) | Drug: Edoxaban|Drug: Standard of Care | Daiichi Sankyo Inc. | Phase 3 | 2017-04-01 | 2017-03-23 |
| NCT02943785 | Atrial Fibrillation | Drug: Edoxaban-based Regimen|Drug: VKA-based Regimen|Drug: VKA-based Regimen|Drug: VKA-based Regimen|Drug: VKA-based Regimen|Drug: VKA-based Regimen|Drug: VKA-based Regimen|Drug: VKA-based Regimen|Drug: VKA-based Regimen|Drug: VKA-based Regimen|Drug: Anti-platelet Therapy | Daiichi Sankyo Inc.|Chiltern International Inc. | Phase 3 | 2017-02-01 | 2016-10-31 |
| NCT01826266 | Anticoagulant Reversal.|Reversal of Edoxaban Induced Anticoagulation. | Drug: PER977, Placebo | Perosphere, Inc. | Phase 1 | 2013-07-01 | 2014-09-25 |
| NCT02047565 | Bleeding | Drug: 60mg edoxaban|Drug: 180mg edoxaban|Drug: 50 IU/kg Beriplex P/N|Drug: 25 IU/kg Beriplex P/N|Drug: 10 IU/kg Beriplex P/N | Daiichi Sankyo Inc. | Phase 1 | 2013-10-01 | 2015-01-14 |
| NCT02618577 | Atrial High Rate Episodes | Drug: Edoxaban|Drug: ASA | German Atrial Fibrillation Network|Daiichi Sankyo Europe, GmbH|Deutsches Zentrum fr Herz-Kreislauf-Forschung (DZHK) | Phase 3 | 2016-02-01 | 2016-09-01 |
